[Detection and evaluation of coronary disease in the diabetic patient].

F. Boccara,A. Cohen

Abstract:

What problem does this paper attempt to address?

A Single Center Experience of in Situ Needle Fenestration of Supra-Aortic Branches During Thoracic Endovascular Aortic Repair.

Yilang Xiang,Chenyang Qiu,Yangyan He,Donglin Li,Tao Shang,Ziheng Wu,Hongkun Zhang

DOI: https://doi.org/10.1016/j.avsg.2019.03.016

IF: 1.5

2019-01-01

Annals of Vascular Surgery

Abstract:Background: To report the early results and technical details of in situ needle fenestration during thoracic endovascular aortic repair (TEVAR). Materials and Methods: Thirty-seven patients with thoracic aortic disease who underwent TEVAR with in situ needle fenestration in our department between February 2016 and April 2017 were included in this study. Their demographic information, clinical manifestations, periprocedural outcomes, and follow-up results were analyzed. Results: In total, 96.4% of attempted fenestrations were successful (53/55). Fenestration of the left subclavian artery (LSA) was performed in 26 patients, fenestration of either the LSA or brachiocephalic trunk (BCT) plus the left common carotid artery (LCCA) was performed in six patients, and fenestration of the three supra-aortic branches was performed in five patients. In the three-fenestration group with five patients, the procedure was under the protection of a cardiopulmonary bypass. External iliac artery rupture occurred in one case. Cerebrovascular events occurred in three cases, and myocardial infarction occurred in one. One case had a branch stent graft stuck in the brachial artery. During a median follow-up of 21 months, two patients developed retrograde type A dissection, and one was subsequently treated with a stent graft and BCT fenestration. One case presented with numbness in the fingertips of the left hand, and computed tomography angiography (CTA) indicated stenosis of the branch stent in the LSA. CTA examination revealed no endoleaks or expansion of the aortic aneurysms in any of the patients. Conclusions: In situ needle fenestration of endografts in the aortic arch is technically feasible, yielding acceptable short-term results in a selected patient cohort. Further studies are needed to determine mid- and long-term outcomes before more widespread adoption.
Antithrombotic therapy for transcatheter structural heart intervention

Paul Guedeney,Josep Rodés-Cabau,Jurriën M Ten Berg,Stephan Windecker,Dominick J Angiolillo,Gilles Montalescot,Jean-Philippe Collet

DOI: https://doi.org/10.4244/EIJ-D-23-01084

2024-08-19

EuroIntervention

Abstract:Percutaneous transcatheter structural heart interventions have considerably expanded within the last two decades, improving clinical outcomes and quality of life versus guideline-directed medical therapy for patients frequently ineligible for surgical treatment. Transcatheter structural heart interventions comprise valve implantation or repair and also occlusions of the patent foramen ovale, atrial septal defects and left atrial appendage. These procedures expose structural devices to arterial or venous blood flow with various rheological conditions leading to potential thrombotic complications and embolisation. Furthermore, these procedures may concern comorbid patients at high risk of both ischaemic and bleeding complications. This state-of-the-art review provides a description of the device-related thrombotic risk associated with these transcatheter structural heart interventions and of the current evidence-based guidelines regarding antithrombotic treatments. Gaps in evidence for each of the studied transcatheter interventions and the main ongoing trials are also summarised.
Left ventricular assist device and transcatheter edge-to-edge mitral valve repair in advanced heart failure: allies or enemies?

S. Valente,C. Sciaccaluga,C. Sorini Dini,F. M. Righini,M. Cameli,S. Bernazzali,M. Maccherini,V. Tarzia,G. Gerosa

DOI: https://doi.org/10.3389/fcvm.2023.1327927

IF: 3.6

2024-01-26

Frontiers in Cardiovascular Medicine

Abstract:The implantation of left ventricular assist devices (LVADs) has been increasing, with good long-term results, in parallel with a growing population with advanced heart failure (HF). However, in some European countries, LVADs are still underused, with one of the main issues being the patient's late referral. On the contrary, the use of transcatheter edge-to-edge mitral valve repair (TEER) has exponentially increased over the past decade, expanding its potential use even in patients on the heart transplantation waiting list. Even though the study populations of the main trials that investigated the prognostic impact of LVAD and TEER are different, in clinical practice a clear distinction might not be so clear. Therefore, patients with refractory HF symptoms and significant mitral regurgitation should be thoroughly evaluated through a multidisciplinary Heart Team meeting with both an advanced HF specialist and interventional cardiologist, to avoid futile procedures and to define the optimal timing for advanced HF therapies, when they are indicated. We analyzed the main available studies and registries on both TEERs and LVADs and we compared their populations and outcomes, to provide the current evidence on the use of LVAD and TEER in the HF population, especially in the light of the recently released 5-year follow-up results, giving some insights on the Italian situation, and finally to stress the importance of a solid HF network between hospitals, aiming for advanced HF patients' timely referral for LVAD or heart transplants.

cardiac & cardiovascular systems
Advancing Cardiac Care: A Registry of Heart Transplantation in Latin America (1968-2022)

Francisco L Uribe-Buritica,Pastor Olaya,Edilma Lucy Rivera,Juan Pablo Cimbaro,Jose Luis Barisani,Pedro Schwartzmann,Fernando Bacal,Víctor Rossel,Elliott Garita Jiménez,Manuel Nafeh Abi-Rezk,Jose Ángel Cigarroa,Eduardo Heberto Herrera Garza,Temístocles Díaz Lezcano,Felipe Nery Fernández,Walter Alarco,Hector Banchs Pieretti,Elaine Núñez,Maximiliano Pereda,Freddy Pow Chon Long,Eglee Castillo Gonzalez,Juan Esteban Gomez-Mesa

DOI: https://doi.org/10.1016/j.transproceed.2024.08.036

Abstract:Introduction: Heart transplantation (HTx) has emerged as a pivotal intervention for end-stage heart failure, offering significant improvements in survival and quality of life. This manuscript elucidates the landscape of HTx across Latin America (LATAM) from its advent in 1968 through December 2022, shedding light on its evolution, current practices, and regional disparities. Methods: We distributed a structured questionnaire to the national coordinators or representatives of the Interamerican Council of Heart Failure and Pulmonary Hypertension, collating responses from 20 LATAM nations. This approach facilitated a comprehensive aggregation of regional HTx data. Results: A total of 12,374 HTx were performed in 166 centers across 16 LATAM countries, with Brazil, Argentina, and Colombia accounting for the majority of procedures. Pediatric transplants represented 9% of the total caseload, and combined organ transplants were reported in 62.5% of the participating countries, underscoring the complexity and breadth of transplant services in the region. Conclusion: Despite facing infrastructural and logistical challenges, LATAM has demonstrated a robust capacity to conduct high-complexity transplant procedures. The establishment of a structured, regional HTx registry is imperative to enhance data collection and analysis, which in turn can inform clinical decision-making and policy development, ultimately improving patient outcomes across the continent.
Characteristics And Clinical Outcomes In Systolic And Diastolic Heart Failure Patients Undergoing Transcatheter Edge-to-edge Repair, Nation-wide Study

Leonid Khokhlov,Fatima Hussain,Mehnaaz Ali,Angel Mena,Amr Aboelnasr,Kenan Rahima,Sindhu Kishore,Sila Mateo-Faxas,Amin Eshghabadi,Mohamad Hijazi,Freidoon Ghazi,Kamal Shemisa,Mohammed Al-Amoodi

DOI: https://doi.org/10.1016/j.cardfail.2023.10.311

IF: 6.592

2024-01-01

Journal of Cardiac Failure

Abstract:Background Transcatheter edge-to-edge repair (TEER) is a minimally invasive approach in the treatment of primary mitral regurgitation. Clinical outcomes in patients undergoing TEER with systolic and diastolic heart failure (HF) have not been yet studied in large data-sets. We sought to investigate this population. Methods We queried NIS between 2017-2020 for adult patients who were underwent TEER and had HFrEF or HFpEF. The primary outcome was inpatient mortality. The secondary outcomes were cardiogenic shock, cardiac arrest, intubation, LOS, and total hospital charge. Multivariable logistic and Poisson regression analyses were used to estimate clinical outcomes. Results There were 23,530 TEER patients with HF: 11,310 (48%) isolated HFrEF and 8135 (34.5%) isolated HFpEF. HFrEF and HFpEF cohorts were with mean age of 73.8 vs 78.5 yrs; males 59.8% vs 50.6%; Caucasians 70.4% vs 79.9%; HTN 2% vs 2.4%; PH 25.2% vs 33.2%; PE 3.3% vs 2.7%; DM 34% vs 27.6%; AF 58.7% vs 64.2%; VFib 1.1% vs 0.2%; CKD 48.5% vs 43.3%; AKI 22% vs 16.9%; obesity 12.2% vs 11.5%; ACS 3.9% vs 3%; PCI 2.7% vs 1.6%; LVAD use 1.1% vs 0.2%; history of MI 22.9% vs 14.2%, respectively. HFrEF cohort was more likely to have cardiogenic shock and had a tendency towards higher mortality (Table 1). Conclusion HFrEF group showed significant propensity to cardiogenic shock and tendency to higher mortality. HFrEF patients were younger, male, with more prevalent PE, DM, CKD, AKI, VFib, obesity, ACS, LVAD use. Isolated systolic dysfunction is associated with cardiometabolic syndrome and cardiac adverse outcomes. Timely identification of cardiac systolic dysfunction might play a role in a risk stratification and prognostication.

cardiac & cardiovascular systems
Impact of left ventricular unloading on postheart transplantation outcomes in patients bridged with VA-ECMO

Daniel Enríquez-Vázquez,Eduardo Barge-Caballero,Francisco González-Vílchez,Luis Almenar-Bonet,María Dolores García-Cosío Carmena,José González-Costello,Manuel Gómez-Bueno,María Ángeles Castel-Lavilla,Beatriz Díaz-Molina,Manuel Martínez-Sellés,Sonia Mirabet-Pérez,Luis de la Fuente-Galán,Daniela Hervás-Sotomayor,Diego Rangel-Sousa,Iris P Garrido-Bravo,Teresa Blasco-Peiró,Gregorio Rábago Juan-Aracil,Javier Muñiz,María G Crespo-Leiro

DOI: https://doi.org/10.1016/j.rec.2024.09.005

2024-10-09

Abstract:Introduction and objectives: The impact of preoperative left ventricular (LV) unloading on postoperative outcomes in patients bridged with venoarterial extracorporeal membrane oxygenation (VA-ECMO) to heart transplantation (HT) is unknown. Our aim was to compare posttransplant outcomes in patients bridged to HT with VA-ECMO, with or without the use of different mechanical strategies for LV decompression. Methods: We conducted a retrospective analysis of the postoperative outcomes of consecutive HT candidates bridged with VA-ECMO, with or without concomitant LV unloading. Patients were included from 16 Spanish centers from 2010 to 2020. The primary endpoint was 1-year post-HT survival, which was assessed using Cox regression. Results: Overall, 245 patients underwent high-emergency HT while supported with VA-ECMO. A mechanical strategy for LV unloading was used in 133 (54.3%) patients, with the intra-aortic balloon pump being the most commonly used method (n=112; 84.2%). One-year posttransplant survival was 74.4% in the LV unloading group and 59.8% in the control group (P=.025). In multivariate analyses, preoperative LV unloading was independently associated with lower 1-year mortality (adjusted HR, 0.50; 95%CI, 0.32-0.78; P=.003). This association was observed both in patients managed with an intra-aortic balloon pump alone (adjusted HR, 0.52; 95%CI, 0.32-0.84; P=.007) and with other strategies for mechanical LV unloading (adjusted HR, 0.43; 95%CI, 0.19-0.97; P=.042). No significant differences were found between groups regarding other postoperative complications. Conclusions: Preoperative LV unloading was independently associated with increased 1-year posttransplant survival in candidates bridged with VA-ECMO.
Characterization and Management of Stable Coronary Artery Disease in Patients Undergoing Transcatheter Aortic Valve Implantation

Sammartino,Laterra,Pilgrim,Santos,De Backer,Kim,Ribeiro,Saia,Bunc,Tchetche,Garot,Ribichini,Mylotte,Burzotta,Watanabe,Bedogni,Tesorio,Rheude,Sardella,Tocci,Franzone,Valvo,Savontaus,Wienemann,Porto,Gandolfo,Iadanza,Bortone,Mach,Latib,Biasco,Taramasso,Marco,Frittitta,Dipietro,Reddavid,Strazzieri,Motta,Comis,Melfa,Calì,Sgroi,Abdel-Wahab,Stefanini,Tamburino,Barbanti,Costa

DOI: https://doi.org/10.3390/jcm13123497

IF: 3.9

2024-06-15

Journal of Clinical Medicine

Abstract:Background/Objectives: To date, data regarding the characteristics and management of obstructive, stable coronary artery disease (CAD) encountered in patients undergoing transcatheter aortic valve implantation (TAVI) are sparse. The aim of the study was to analyze granular details, treatment, and outcomes of patients undergoing TAVI with obstructive, stable CAD from real-world practice. Methods: REVASC-TAVI (Management of myocardial REVASCularization in patients undergoing Transcatheter Aortic Valve Implantation with coronary artery disease) is an investigator-initiated, multicenter registry, which collected data from patients undergoing TAVI with obstructive stable CAD found during the pre-TAVI work-up. Results: A total of 2025 patients from 30 centers worldwide with complete follow-up were included in the registry. Most patients had single-vessel CAD (56.1%). An involvement of proximal coronary tracts was detected in 62.5% of cases, with 12.0% of patients having CAD in left main (LM). Most patients received percutaneous coronary intervention (PCI) (n = 1617, 79.9%), especially those with proximal CAD (90.4%). At 2 years, the rates of all-cause death [Kaplan–Meier (KM) estimates 20.1% vs. 18.8%, plog-rank = 0.86] and of the composite of all-cause death, stroke, myocardial infarction, and rehospitalization for heart failure (KM estimates 29.7% vs. 27.5%, plog-rank = 0.82) did not differ between patients undergoing PCI and those who were not. Conclusions: Patients undergoing TAVI with obstructive CAD more commonly had a single-vessel disease and an involvement of proximal coronary tracts. They were commonly treated with PCI, with similar outcomes compared to those treated conservatively.

medicine, general & internal
Degradation of Phenol via Phenylphosphate and Carboxylation to 4-Hydroxybenzoate by a Newly Isolated Strain of the Sulfate-Reducing Bacterium Desulfobacterium anilini

Y. Ahn,J. Chae,G. Zylstra,M. Häggblom

DOI: https://doi.org/10.1128/AEM.00203-09

2009-05-01

Applied and Environmental Microbiology

Abstract:ABSTRACT A sulfate-reducing phenol-degrading bacterium, strain AK1, was isolated from a 2-bromophenol-utilizing sulfidogenic estuarine sediment enrichment culture. On the basis of phylogenetic analysis of the 16S rRNA gene and DNA homology, strain AK1 is most closely related to Desulfobacterium anilini strain Ani1 (= DSM 4660T). In addition to phenol, this organism degrades a variety of other aromatic compounds, including benzoate, 2-hydroxybenzoate, 4-hydroxybenzoate, 4-hydroxyphenylacetate, 2-aminobenzoate, 2-fluorophenol, and 2-fluorobenzoate, but it does not degrade aniline, 3-hydroxybenzoate, 4-cyanophenol, 2,4-dihydroxybenzoate, monohalogenated phenols, or monohalogenated benzoates. Growth with sulfate as an electron acceptor occurred with acetate and pyruvate but not with citrate, propionate, butyrate, lactate, glucose, or succinate. Strain AK1 is able to use sulfate, sulfite, and thiosulfate as electron acceptors. A putative phenylphosphate synthase gene responsible for anaerobic phenol degradation was identified in strain AK1. In phenol-grown cultures inducible expression of the ppsA gene was verified by reverse transcriptase PCR, and 4-hydroxybenzoate was detected as an intermediate. These results suggest that the pathway for anaerobic degradation of phenol in D. anilini strain AK1 proceeds via phosphorylation of phenol to phenylphosphate, followed by carboxylation to 4-hydroxybenzoate. The details concerning such reaction pathways in sulfidogenic bacteria have not been characterized previously.
Impact of mitral transcatheter edge-to-edge repair in patients with advanced heart failure evaluated for heart transplantation

C Urbano Sanchez,F Esteban Martinez,M Ruiz Ortiz,M Delgado Ortega,A M Rodriguez Almodovar,N Aguayo Cano,L Barreiro Mesa,A Roldan Guerra,A Moran,R Gonzalez Manzanares,J Pera Armijo,S Ojeda Pineda,J Suarez De Lezo Herreros De Tejada,M Pan Alvarez-Osorio,D Mesa Rubio

DOI: https://doi.org/10.1093/eurheartj/ehae666.1137

IF: 39.3

2024-10-30

European Heart Journal

Abstract:Background Heart transplantation is sometimes the only therapeutic option in patients with advanced heart failure (HF), impaired ventricular function and significant functional or secondary mitral regurgitation (MR). The shortage of organs and the limitations of the recipient make it necessary to consider other therapeutic alternatives in these patients, such as mitral transcatheter edge-to-edge repair (M-TEER). The MitraBridge registry has recently been published in which they analyze the potential effect of M-TEER in patients with advanced HF and moderate-severe MI who are candidates for heart transplantation (mean age 59 years, left ventricular ejection fraction (LVEF) 27%); after a mean follow-up of 24 months, complete in 82.4%, they report an overall survival of 78.5%, a combined event-free survival of 47%, with a 6.5 % need for urgent transplantation and an HF hospitalization rate after M-TEER of 44/100 patient-years. The aim of our study is to assess the impact of M-TEER on mortality and the combined events of death, HF rehospitalization and the need for urgent transplantation or a ventricular assistance device in patients with moderate-severe functional MI and advanced HF who have also been evaluated for cardiac transplantation in our hospital. Methods This is a retrospective analysis of a prospective registry. Of the patients treated by M-TEER for severe MI, we selected those with advanced HF (defined as LVEF≤35%, and/or advanced functional class (NYHA III-IV)) who had also been evaluated as possible candidates for inclusion in the heart transplant list. Results From November 2011 to December 2023, 191 patients were treated by M-TEER, of whom 38 patients met the established criteria (median age 59 years [48-65], 31 (81%) males, mean LVEF was 26 ± 6%). All patients had at least one previous hospitalization for HF and optimal medical treatment according to guidelines; the rest of the baseline clinical characteristics are listed in Table 1. During the follow-up after M-TEER, with a median of 34 months [7-70], the probability of overall survival at 2 years was 75.6%. The combined endpoint of death, need for urgent transplantation or a ventricular assist device, and rehospitalization for heart failure occurred in 26 patients with a 2-year event-free survival probability of 48% (Figure 1). Five patients (13%) were transplanted, one (2.6%) urgently. Prior to M-TEER therapy, the rate of HF hospitalization was 108 hospitalizations/100 patient-years, which was significantly reduced after the procedure to 33 hospitalizations/100 patient-years (rate ratio 0.31 [95% CI 0.21-0.45, p<0.0005]). Conclusions In patients with advanced HF and severe functional MR who are candidates for cardiac transplantation, M-TEER is an effective therapeutic alternative, achieving a survival rate of more than three-quarters of the patients at 2 years of follow-up, a significant reduction in HF hospitalizations, and a low rate of need for cardiac transplantation.

cardiac & cardiovascular systems
Performance of balloon-expandable transcatheter bioprostheses in inoperable patients with pure aortic regurgitation of a native valve: The BE-PANTHEON international project

Enrico Poletti,Ignacio Amat-Santos,Enrico Criscione,Antonio Popolo Rubbio,Mario García-Gómez,Mateusz Orzalkiewicz,Manuel Pan,Antonio Sisinni,Mattia Squillace,Bruno García Del Blanco,Francesco Bruno,Vasileios Panoulas,Radoslaw Pracon,Ole De Backer,Maurizio Taramasso,Giuliano Costa,Marco Barbanti,Nicolas M Van Mieghem,Damiano Regazzoli,Antonio Mangieri,Andrea Scotti,Azeem Latib,Francesco Saia,Francesco Bedogni,Luca Testa

DOI: https://doi.org/10.1016/j.carrev.2024.08.007

2024-08-22

Abstract:Background: The off-label utilization of transcatheter heart valve (THV) devices for the treatment of inoperable or high-surgical risk patients with pure native aortic valve regurgitation (NAVR) has demonstrated suboptimal outcomes, both with self- and balloon-expandable (BE) devices. The aim of this study is to compare the use of different BE scaffolds in treating pure NAVR. Methods: Consecutive patients with pure severe NAVR who were deemed to be at high-risk and were treated with last-generation BE-THVs among seventeen Centers in Europe and US. Technical and device success rates were the primary objectives. Results: Between February 2018 and July 2023, among 144 patients, 41 (28 %) received a MyVal device and 103 (72 %) were treated with a Sapien THV. Patients treated with a MyVal THV had an extra-large annulus more frequently compared to the Sapien group (49%vs.20 %, p < 0.001). Technical and device success rates were 90 % and 81 %, respectively, p > 0.1. The rate of THV migration/embolization (MyVal 4.9%vs. Sapien 11 %, p = 0.4) and second valve needed (4.9%vs.7.8 %, p = 0.7) were numerically lower in the MyVal group, whereas the rate of at least moderate paravalvular leak (15%vs.7.8 %, p = 0.2) and permanent pacemaker implantation (25%vs.18 %, p = 0.16) were numerically higher in the Myval group. Conclusions: Off-label use of BE devices for pure NAVR represents a potential alternative in high-risk patients in the absence of dedicated devices. However, BE in NAVR is associated with suboptimal outcomes. The availability of larger THV sizes may introduce transcatheter aortic valve replacement as an effective treatment for patients traditionally deemed unsuitable. Non-standard abbreviations and acronyms: AR = aortic regurgitation, BE = balloon-expandable, NAVR = native aortic valve regurgitation, PM = pacemaker, TAVR = transcatheter aortic valve replacement, THV = transcatheter heart valve, TVEM = transcatheter valve embolization and migration, VARC-3 = Valve Academic Research Consortium 3.
CharActeristics, sizing anD outcomes of stenotic, tapered, rapHe-type bicuspid aOrtic valves treated with trans-catheter device implantation: Insights the AD HOC registry

Andrea Buono,Chiara De Biase,Tommaso Fabris,Michele Bellamoli,Won-Keun Kim,Nicholas Montarello,Giuliano Costa,Andrea Zito,Mesfer Alfadhel,Ofir Koren,Simone Fezzi,Barbara Bellini,Mauro Massussi,Andrea Scotti,Lin Bai,Giulia Costa,Alessandro Mazzapicchi,Enrico Giacomin,Riccardo Gorla,Alessia Latini,Chiara Fraccaro,Lars Sondergaard,Orazio Strazzieri,Mauro Boiago,Marco Busco,Efstratios Charitos,Ady Orbach,Antonio Messina,Luca Bettari,Edoardo Navazio,Donato Antonio Paglianiti,Takashi Nagasaka,Massimo Napodano,Emmanuel Villa,Marco Angelillis,Alfonso Ielasi,Uri Landes,Nedy Brambilla,Francesco Bedogni,Antonio Mangieri,Francesco Saia,Luca Favero,Mao Chen,Marianna Adamo,Azeem Latib,Anna Sonia Petronio,Matteo Montorfano,Raj R Makkar,Darren Mylotte,Daniel J Blackman,Marco Barbanti,Ole De Backer,Didier Tchètchè,Diego Maffeo,Giuseppe Tarantini

DOI: https://doi.org/10.1016/j.ijcard.2024.132569

2024-12-15

Abstract:Background: Raphe-type bicuspid aortic valve (BAV) is a potential hostile scenario in trans-catheter aortic valve replacement (TAVR) due to pronounced calcium burden, possibly associated with tapered valve configuration. Trans-Catheter heart valve (THV) sizing strategy (annular vs. supra-annular) is controversial in this valve subtype. Objectives: To describe the phenotypical characteristics of severe, tapered, raphe-type, BAV stenosis undergoing TAVR and to explore safety and efficacy of modern-generation THVs, analysing the impact of annular and supra-annular sizing strategies on short- and mid-terms outcomes. Methods: This is a retrospective, multicenter registry enrolling consecutive stenotic Sievers type 1 BAV treated with TAVR. Study population was divided into tapered and non-tapered configuration according to MSCT analysis. Matched comparison between annular and supra-annular sizing groups was performed in tapered population. Results: From January 2016 to June 2023, 897 patients were enrolled. Of them, 696 patients displayed a tapered configuration. Of those, 510 received a THV according to annular sizing. After propensity score matching 186 matched pairs were selected. Technical success (96.2 % vs 94.1 %, OR 1.61 [0.61-4.24], p = 0.34), 30-day device success (83.6 % in both groups, OR 1.42 [0.78-2.57], p = 0.25) and 30-day early safety (71.8 % vs 70.5 %, OR 1.07 [0.68-1.68], p = 0.78) were similar between the annular and supra-annular sizing groups; a higher post-TAVR gradient was observed in supra-annular group, although it was only 2 mmHg mean. At mid-term follow-up, the rate of clinical efficacy was 84.7 %. Conclusions: TAVR with modern-generation devices is safe and effective for tapered raphe-type BAV, showing comparable results for annular and supra-annular sizing strategies.
"Durable Left Ventricular Assist Devices as a Bridge to Transplantation in The Old and The New World"

Andrea Fernandez Valledor,Gal Rubinstein,Cathrine M. Moeller,Daniel Lorenzatti,Salwa Rahman,Changhee Lee,Daniel Oren,Marta Farrero,Gabriel T. Sayer,Nir Uriel

DOI: https://doi.org/10.1016/j.healun.2024.01.019

IF: 13.569

2024-02-15

The Journal of Heart and Lung Transplantation

Abstract:Introduction Heart transplantation remains the gold standard treatment for end-stage heart failure patients without contraindications. However, limited donor availability and long wait times have created a need for left ventricular assist devices (LVAD) to be used as a bridge to transplantation (BTT) in appropriately selected patients. Methods This review provides an overview of the current state of heart transplantation in the US and Europe, with a particular focus on how distinct allocation policies and organ availability impact medical practices. Results LVAD utilization as BTT exhibits notable disparities worldwide, mainly due to variations in organ availability, allocation policies, and financial constraints. Although Europe has experienced a consistent increase in the use of LVAD for this purpose, the United Network for Organ Sharing 2018 policy amendment resulted in a significant reduction in the number of LVADs used for BTT in the US. Discussion Given the features of the US transplant allocation system, the BTT indication is likely to remain as a minority. To overcome this issue, modifications in the US allocation policy to consider factors such as days on device support, age, and type of complications may be necessary to potentially increase implantation rates. Meanwhile, due to a shortage of donors and the increasing expertise in the advanced heart failure field, the utilization of LVAD in Europe is expected to see gradual growth.

surgery,cardiac & cardiovascular systems,respiratory system,transplantation
Performance of the heart team approach in daily clinical practice in high-risk patients with aortic stenosis

Gabriela Tirado-Conte,Carolina Espejo-Paeres,Luis Nombela-Franco,Pilar Jimenez-Quevedo,Javier Cobiella,David Vivas,Jose Alberto de Agustín,Angela McInerney,Eduardo Pozo,Pablo Salinas,Ivan Nuñez-Gil,Nieves Gonzalo,Enrique Villagran,Alfonso de Hoyos,Hernán Mejia-Renteria,Fernando Macaya,Manuel Carnero,Isidre Vilacosta,Antonio Fernández-Ortiz,Javier Escaned,Luis Maroto,Carlos Macaya

DOI: https://doi.org/10.1111/jocs.15116

Abstract:Objective: The heart team (HT) approach plays a key role in selecting the optimal treatment strategy for patients with aortic stenosis (AS). However, little is known about the HT decision process and its impact on outcomes. The aim of this study was to identify the factors associated with the HT decision and evaluate clinical outcomes according to the treatment choice. Methods: The study included a total of 286 consecutive patients with AS referred for discussion in the weekly HT meeting in a cardiovascular institute over 2 years. Patients were stratified according to the selected therapeutic approach: medical treatment (MT), surgical (SAVR), or transcatheter (TAVR) aortic valve replacement. Baseline characteristics involved in making a therapeutic choice were identified and a decision-making tree was built using classification and regression tree methodology. Results: Based on HT discussion, 53 patients were assigned to SAVR, 210 to TAVR, and 23 to MT. Older patients (≥88 years old) were mainly assigned to TAVR or MT according to the logistic EuroSCORE (<or≥28, respectively). While among younger patients (<88 years), significant mitral regurgitation (≥grade III), frailty, Society of Thoracic Surgeons score, and estimated glomerular filtration rate were the most relevant factors influencing treatment allocation. One-year all-cause mortality was 16.6% in the invasive groups (TAVR = 17.2%, SAVR = 14.0%) and 68.7% in the MT arm. Conclusion: The HT decision was determined by well-recognized risk factors that were used to define a treatment decision algorithm. Future studies with younger and lower-risk patients may identify new contributory factors that may alter the selection process and treatment choice.
Clinical impact of complex percutaneous coronary intervention in the pre-TAVR workup

Marisa Avvedimento,Francisco Campelo-Parada,Luis Nombela-Franco,Quentin Fischer,Pierre Donaint,Vicenç Serra,Gabriela Veiga,Enrique Gutiérrez,Anna Franzone,Victoria Vilalta,Alberto Alperi,Ander Regueiro,Lluis Asmarats,Henrique B Ribeiro,Anthony Matta,Antonio Muñoz-García,Gabriela Tirado,Marina Urena,Damien Metz,Eduard Rodenas-Alesina,Jose María de la Torre Hernández,Domenico Angellotti,Eduard Fernández-Nofrerías,Isaac Pascual,Pablo Vidal-Calés,Dabit Arzamendi,Diego Carter Campanha-Borges,Kim Hoang Trinh,Jorge Nuche,Mélanie Côté,Laurent Faroux,Josep Rodés-Cabau

DOI: https://doi.org/10.1016/j.rec.2024.05.002

2024-05-17

Abstract:Introduction and objectives: In patients undergoing percutaneous coronary intervention (PCI) in the workup pre-transcatheter aortic valve replacement (TAVR), the clinical impact of coronary revascularization complexity remains unknown. This study sought to examine the impact of PCI complexity on clinical outcomes after TAVR in patients undergoing PCI in the preprocedural workup. Methods: This was a multicenter study including consecutive patients scheduled for TAVR with concomitant significant coronary artery disease. Complex PCI was defined as having at least 1 of the following features: 3 vessels treated, ≥ 3 stents implanted, ≥ 3 lesions treated, bifurcation with 2 stents implanted, total stent length >60mm, or chronic total occlusion. The rates of major adverse cardiac events (MACE), including cardiovascular mortality, myocardial infarction, and coronary revascularization were evaluated. Results: A total of 1550 patients were included, of which 454 (29.3%) underwent complex PCI in the pre-TAVR workup. After a median follow-up period of 2 [1-3] years after TAVR, the incidence of MACE was 9.6 events per 100 patients-years. Complex PCI significantly increased the risk of cardiac death (HR, 1.44; 95%CI, 1.01-2.07), nonperiprocedural myocardial infarction (HR, 1.52; 95%CI, 1.04-2.21), and coronary revascularization (HR, 2.46; 95%CI, 1.44-4.20). In addition, PCI complexity was identified as an independent predictor of MACE after TAVR (HR, 1.31; 95%CI, 1.01-1.71; P=.042). Conclusions: In TAVR candidates with significant coronary artery disease requiring percutaneous treatment, complex revascularization was associated with a higher risk of MACE. The degree of procedural complexity should be considered a strong determinant of prognosis in the PCI-TAVR population.
Decreased incidence of papillomas in mice with impaired EGFR function during multi‐stage skin carcinogenesis

M. Dahlhoff,C. Rose,E. Wolf,M. Schneider

DOI: https://doi.org/10.1111/j.1600-0625.2010.01192.x

2011-03-01

Experimental Dermatology

Abstract:Abstract: Genetically modified mouse lines revealed that the epidermal growth factor receptor (EGFR) is essential for the development and homoeostasis of the epidermis and hair follicles. However, more detailed studies have been precluded by the shortened lifespan of Egfr knockout mice. We employed the mouse line Wa5 (carrying a point mutation resulting in the expression of a dominant negative receptor) to analyse the impact of significantly reduced EGFR signalling during multi‐stage chemical skin carcinogenesis. Seven‐week‐old Wa5 females and control littermates received a single application of 7,12‐dimethylbenz(a)anthracene followed by multiple applications of 12‐O‐tetradecanoylphorbol‐13‐acetate for 26 weeks. Wa5 mice remained free of papillomas for a longer time and developed significantly fewer tumors than control littermates. In contrast, the mean tumor size was not different between groups. The present data indicate that EGFR signalling contributes to tumor growth during multi‐stage chemical carcinogenesis of the skin in mice possibly by acting as a survival factor for skin tumor cells.
Antithrombotic Therapy Following Structural Heart Disease Interventions: Current Status and Future Directions

Andreas Mitsis,Michaela Kyriakou,Evi Christodoulou,Stefanos Sakellaropoulos,Panayiotis Avraamides

DOI: https://doi.org/10.31083/j.rcm2502060

2024-02-05

Reviews in Cardiovascular Medicine

Abstract:Interventions in structural heart disease cover many catheter-based procedures for congenital and acquired conditions including valvular diseases, septal defects, arterial or venous obstructions, and fistulas. Among the available procedures, the most common are aortic valve implantation, mitral or tricuspid valve repair/implantation, left atrial appendage occlusion, and patent foramen ovale closure. Antithrombotic therapy for transcatheter structural heart disease interventions aims to prevent thromboembolic events and reduce the risk of short-term and long-term complications. The specific approach to antithrombotic therapy depends on the type of intervention and individual patient factors. In this review, we synopsize contemporary evidence on antithrombotic therapies for structural heart disease interventions and highlight the importance of a personalized approach. These recommendations may evolve over time as new evidence emerges and clinical guidelines are updated. Therefore, it’s crucial for healthcare professionals to stay updated on the most recent guidelines and individualize therapy based on patient-specific factors and procedural considerations.

cardiac & cardiovascular systems
Requiem for the cholecystokinin provocation test.

W. Murray

DOI: https://doi.org/10.1136/gut.44.4.579-e

IF: 24.5

Gut

Abstract:
Transcatheter management of pure native aortic valve regurgitation in patients with Left-Ventricular assist device

Hristian Hinkov,Chong Bin Lee,Leonard Pitts,Pia Lanmüller,Christoph Klein,Marian Kukucka,Evgenij Potapov,Jörg Kempfert,Volkmar Falk,Henryk Dreger,Axel Unbehaun

DOI: https://doi.org/10.1093/ejcts/ezae028

IF: 4.534

2024-01-25

European Journal of Cardio-Thoracic Surgery

Abstract:Abstract OBJECTIVES Aortic valve regurgitation (AR) frequently complicates the clinical course after left-ventricular assist device (LVAD) implantation. Transcatheter aortic valve implantation (TAVI) has emerged as an alternative to surgical aortic valve replacement (SAVR) in this cohort with a mostly high surgical risk profile. The unique challenges in LVAD patients, such as presence of non-calcified aortic valves and annular dilatation, raise concerns about device migration and paravalvular leakage (PVL) leading to missing device success. This study evaluates procedural outcomes and survival rates in LVAD patients who underwent TAVI, emphasizing strategies to enhance device success. Methods Between January 2017 and April 2023, 27 LVAD patients with clinically significant AR underwent elective or urgent TAVI at our centre. Primary end-points were procedural success rates, without the need for a second transcatheter heart valve (THV) and postprocedural AR/PVL. Secondary outcomes included survival rates and adverse events. Results Among the cohort, 14.8% received AR-dedicated TAVI devices, with none requiring a second THV. There was no intraprocedural AR, and one patient (25%) had AR > “trace” at discharge. Additionally, 25.9% underwent device landing zone (DLZ) pre-stenting with a standard TAVI device, all without needing a second THV. There was no intraprocedural AR, and none to trace AR at discharge. Among the 59.3% receiving standard TAVI devices, 37.5% required a second THV. In this subgroup, intraprocedural AR > “trace” occurred in 12.5%, decreasing to 6.25% at discharge. In-hospital mortality was 3.7%, and median follow-up survival was 388 days (IQR 208–1167 days). Conclusions TAVI yields promising procedural outcomes and early survival rates in LVAD patients with AR. Tailored TAVI devices and pre-stenting techniques enhance procedural success. Continued research into these strategies is essential to optimize outcomes in this complex patient cohort.

surgery,cardiac & cardiovascular systems,respiratory system
Reply to: "Updated diagnostic criteria for frontal fibrosing alopecia".

Stanislav N Tolkachjov,Hafsa M. Chaudhry,R. Imhof,M. Camilleri,R. Torgerson

DOI: https://doi.org/10.1016/j.jaad.2017.09.027

Abstract:
Transcatheter Interventions in Adults With Fontan Palliation

Eduardo Flores-Umanzor,Raquel Luna-López,Pedro Cepas-Guillen,Sílvia Montserrat,Bandar Alshehri,Rajesh Keshvara,Lusine Abrahamyan,Juan M. Carretero Bellón,Rafael Alonso-Gonzalez,Mark Osten,Xavier Freixa,Josep Rodes-Cabau,Lee Benson,Eric Horlick

DOI: https://doi.org/10.1161/circinterventions.124.014699

2024-11-28

Circulation Cardiovascular Interventions

Abstract:Circulation: Cardiovascular Interventions, Ahead of Print. The Fontan circuit is associated with chronically elevated systemic venous pressures and decreased cardiac output, often leading to circuit failure. Managing Fontan circuit failure is complex and requires multiple therapeutic options. Transcatheter interventions have emerged as a reliable approach. They can alleviate obstructions and improve cyanosis by enhancing pulmonary blood flow and oxygen saturation. These procedures can also increase cardiac output and reduce systemic venous pressure, contributing to patient stabilization. In addition, they help mitigate volume overload and decrease the risk of bleeding during heart or combined heart and liver transplants. In recent years, percutaneous interventions have rapidly evolved and become a key therapeutic option for addressing various aspects of Fontan circuit failure. These interventions should be considered integral to the management strategy for this specific patient population.

cardiac & cardiovascular systems

[Detection and evaluation of coronary disease in the diabetic patient].

A Single Center Experience of in Situ Needle Fenestration of Supra-Aortic Branches During Thoracic Endovascular Aortic Repair.

Antithrombotic therapy for transcatheter structural heart intervention

Left ventricular assist device and transcatheter edge-to-edge mitral valve repair in advanced heart failure: allies or enemies?

Advancing Cardiac Care: A Registry of Heart Transplantation in Latin America (1968-2022)

Characteristics And Clinical Outcomes In Systolic And Diastolic Heart Failure Patients Undergoing Transcatheter Edge-to-edge Repair, Nation-wide Study

Impact of left ventricular unloading on postheart transplantation outcomes in patients bridged with VA-ECMO

Characterization and Management of Stable Coronary Artery Disease in Patients Undergoing Transcatheter Aortic Valve Implantation

Degradation of Phenol via Phenylphosphate and Carboxylation to 4-Hydroxybenzoate by a Newly Isolated Strain of the Sulfate-Reducing Bacterium Desulfobacterium anilini

Impact of mitral transcatheter edge-to-edge repair in patients with advanced heart failure evaluated for heart transplantation

Performance of balloon-expandable transcatheter bioprostheses in inoperable patients with pure aortic regurgitation of a native valve: The BE-PANTHEON international project

CharActeristics, sizing anD outcomes of stenotic, tapered, rapHe-type bicuspid aOrtic valves treated with trans-catheter device implantation: Insights the AD HOC registry

"Durable Left Ventricular Assist Devices as a Bridge to Transplantation in The Old and The New World"

Performance of the heart team approach in daily clinical practice in high-risk patients with aortic stenosis

Clinical impact of complex percutaneous coronary intervention in the pre-TAVR workup

Decreased incidence of papillomas in mice with impaired EGFR function during multi‐stage skin carcinogenesis

Antithrombotic Therapy Following Structural Heart Disease Interventions: Current Status and Future Directions

Requiem for the cholecystokinin provocation test.

Transcatheter management of pure native aortic valve regurgitation in patients with Left-Ventricular assist device

Reply to: "Updated diagnostic criteria for frontal fibrosing alopecia".

Transcatheter Interventions in Adults With Fontan Palliation